Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Hold” from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned a consensus rating of “Hold” from the nine analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $20.50.

KROS has been the subject of several research analyst reports. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 5th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Leerink Partners cut their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Wells Fargo & Company cut their price target on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, August 4th. Finally, Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $11.36 on Tuesday. Keros Therapeutics has a 52-week low of $9.69 and a 52-week high of $22.55. The company has a market capitalization of $225.27 million, a P/E ratio of -3.07 and a beta of 1.12. The company has a 50-day simple moving average of $10.96 and a 200 day simple moving average of $11.04.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, equities analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its Board of Directors has authorized a stock buyback plan on Wednesday, September 9th that authorizes the company to repurchase $5.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 2.3% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity

In related news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. The trade was a 11.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 5,343 shares of company stock worth $54,985. Company insiders own 12.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new stake in Keros Therapeutics during the second quarter worth approximately $334,000. Hsbc Holdings PLC boosted its holdings in shares of Keros Therapeutics by 29.5% during the second quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock worth $761,000 after acquiring an additional 15,940 shares during the period. Nantahala Capital Management LLC acquired a new position in shares of Keros Therapeutics in the second quarter valued at approximately $15,091,483. Empowered Funds LLC acquired a new position in shares of Keros Therapeutics in the second quarter valued at approximately $1,521,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Keros Therapeutics during the second quarter worth approximately $538,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing medicines that regulate signaling within the transforming growth factor beta (TGF-β) superfamily. The company’s research is aimed at addressing diseases in which abnormal signaling affects blood-cell production, bone health, muscle function, or cardiovascular health.

Keros has developed investigational ligand-trap therapies designed to modify signaling by activin and related proteins.